IRVINE, Calif., Oct. 31, 2023 /PRNewswire/ -- VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced that William T. Lowrance, MD, MPH, MBA will serve as the company's Chief Medical Officer.

加利福尼亚州欧文市，2023年10月31日/PRNewswire/-VESICA HEALTH，INC.，一家多组学，液体活检公司，改变了血尿患者的管理并改善了膀胱癌的早期发现，今天宣布William T.Lowrance，医学博士，公共卫生硕士，工商管理硕士将担任该公司的首席医疗官。

Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials..

Lowrance博士拥有20多年的临床经验，担任泌尿外科教授和泌尿外科肿瘤学家，治疗患者并进行临床试验。。

Continue Reading

继续阅读

'We are privileged to welcome Dr. Lowrance to Vesica Health. His expertise in urology and extensive experience in conducting clinical trials, as well as his deep understanding of the challenges associated with urologic malignancies, make him an invaluable addition to our team,' commented Christopher Thibodeau, CEO of Vesica Health.

“我们很高兴欢迎Lowrance博士参加Vesica Health。他在泌尿外科方面的专业知识和进行临床试验的丰富经验，以及他对泌尿系统恶性肿瘤相关挑战的深刻理解，使他成为我们团队的宝贵补充，“Vesica Health首席执行官Christopher Thibodeau评论道。

Thibodeau emphasized that ~ 20,000 bladder cancer cases are missed every year under the current standard of care, leading to more advanced disease and higher mortality rates, and that patients deserve better. 'Dr. Lowrance will play a vital role in shaping our clinical strategy, creating a strong patient-centric organization, and contributing to our mission of transforming the management of hematuria patients and improving the early detection of bladder cancer,' he continued..

Thibodeau强调，在目前的护理标准下，每年约有2万例膀胱癌病例被漏诊，导致更晚期的疾病和更高的死亡率，患者应该得到更好的治疗Lowrance博士将在塑造我们的临床策略，创建一个强大的以患者为中心的组织方面发挥至关重要的作用，并为我们改变血尿患者管理和改善膀胱癌早期发现的使命做出贡献，“他继续。。

Well-validated genomic tests like AssureDx will fundamentally change the diagnosis and management of bladder cancer

经过充分验证的基因组测试，如AssureDx，将从根本上改变膀胱癌的诊断和治疗

Post this

发布这个

'I have devoted my career to researching and treating urologic cancers, striving to improve patient care and ultimately, survival,' said Dr. William T. Lowrance, Chief Medical Officer of Vesica Health. 'I am truly honored to join the management team at Vesica and contribute to our shared mission of supporting those battling bladder cancer.

“我的职业生涯致力于研究和治疗泌尿系统癌症，努力改善患者护理并最终提高生存率，”Vesica Health首席医疗官William T.Lowrance博士说我真的很荣幸加入Vesica的管理团队，并为我们支持那些与膀胱癌作斗争的共同使命做出贡献。

We are at a pivotal moment with the advent of well-validated genomic tests like AssureDx, which hold the promise of fundamentally changing the diagnosis and management of bladder cancer. By identifying patients at an increased risk of developing the disease at an early stage, when treatment is most effective, we can offer hope and support to those in need.'.

我们正处于关键时刻，像SurSurSureDx这样经过充分验证的基因组测试的出现，它有望从根本上改变膀胱癌的诊断和治疗。通过在早期发现患病风险增加的患者，当治疗最有效时，我们可以为有需要的人提供希望和支持。

Dr. Lowrance is an attending urologic oncologist at Bon Secours Mercy Health, specializing in the treatment of urologic malignancies, with a focus on bladder cancer. Formerly, he served as Associate Professor of Urology and the leader of the Genitourinary Disease Center at Huntsman Cancer Institute at the University of Utah, and previously as an Adjunct Faculty Instructor of Surgery, at Memorial Sloan-Kettering Cancer Center in New York.

Lowrance博士是Bon-Secours Mercy Health的主治泌尿肿瘤学家，专门从事泌尿系统恶性肿瘤的治疗，重点是膀胱癌。此前，他曾在犹他大学亨斯曼癌症研究所担任泌尿外科副教授和泌尿生殖系统疾病中心负责人，并曾在纽约Memorial Sloan Kettering癌症中心担任外科副教师。

Dr. Lowrance earned his Master of Business Administration from the David Eccles School of Business at the University of Utah, a Master of Public Health from Harvard School of Public Health, a Medical Degree from the Medical University of South Carolina, and a BA in Chemistry from Washington and Lee University.

Lowrance博士获得了犹他大学David Eccles商学院的商业管理硕士学位，哈佛大学公共卫生学院的公共卫生硕士学位，南卡罗来纳医科大学的医学学位以及化学学士学位来自华盛顿和李大学。

He performed his urology residency at Vanderbilt University Medical Center and his Fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center. Dr. Lowrance's research focuses on understanding and improving patient clinical outcomes and has published numerous peer-reviewed urologic articles, book chapters, and editorials.While serving as the Chief Medical Officer of Vesica Health, Dr.

他在范德比尔特大学医学中心进行泌尿外科住院治疗，并在斯隆-凯特琳纪念癌症中心获得泌尿肿瘤学奖学金。Lowrance博士的研究重点是理解和改善患者的临床结果，并发表了许多同行评审的泌尿外科文章，书籍章节和社论。作为Vesica Health的首席医疗官。

Lowrance will continue his medical practice at Bon Secours Mercy Health. He is the chair of the American Urological Association's Advanced Prostate Cancer Clinical Guidelines committee and has served on the editorial board for multiple medical journals. He peer reviews medical manuscripts for a variety of medical journals. About AssureDx™Vesica Health's patented, noninvasive, urine-based AssureDx test helps physicians accurately triage hematuria patients, distinguishing those at increased risk for bladder cancer, who may benefit from immediate referral to urology and clinical evaluation, from those at very low risk for bladder cancer, w.

Lowrance将在Bon-Secours Mercy Health继续他的医疗实践。他是美国泌尿学协会高级前列腺癌临床指南委员会的主席，并曾在多种医学期刊的编辑委员会任职。他同行评审各种医学期刊的医学手稿。关于确保dx™Vesica Health公司获得专利，无创，基于尿液的SurfedX检测可帮助医生准确分类血尿患者，区分那些可能从泌尿科和临床评估立即转诊中受益的膀胱癌风险增加的患者和膀胱癌风险极低的患者，w。